ClinicalTrials.gg
Not yet recruitingNCT07517289Updated Apr 8, 2026

Study to Determine the Comparative Pharmacodynamics of Enoxaparin Sodium Biosimilar With That From Clexane

A Phase 1 interventional study of Enoxaparin 40 Mg/0.4 mL Injectable Solution in Healthy Participants Study and The Focus of the Study is to Determine the Comparative Pharmacodynamic of Enoxaparin Sodium With That of Clexane in Healthy Human Participants, sponsored by Egyptian International Pharmaceutical Industries Co. Not yet recruiting. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Egyptian International Pharmaceutical Industries Co · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
21 Years to 55 Years
Sex
All
01

Study summary

An Open-Label, Single-center, Randomized, Single-Dose, Two-Way Crossover Biosimilarity Study to Determine the Comparative Pharmacodynamics of Enoxaparin Sodium Biosimilar 40mg/0.4ml with that from the Reference IMP, Clexane® (40 mg/0.4ml), Following Single-Dose Administration in Healthy Participants. Test: Enoxaparin Sodium (Enoxaparin Sodium 40mg/0.4ml) manufactured by EIPICO, Egypt. Reference: Clexane (Enoxaparin Sodium 40mg/0.4ml) manufactured by Sanofi Aventis, Egypt. Primary objective:

To assess biosimilarity between a single dose from the test product versus the reference product in healthy participants

Secondary objective:

To investigate the safety and tolerability of the formulations. This study is a randomized single-dose, two-way, two-period, two-sequence, crossover biosimilarity study with a washout period of one week after each dosing.A minimum of 21 healthy adult male and female participants from Egyptian population will be enrolled in this study, along with 5 additional participants to account for potential dropouts or withdrawal. 26 Participants plus 1-4 alternates will be admitted to the study. An alternate participant will be dosed by the same sequence as the withdrawn participant only if any participant of the first 26 Participants withdraws before the first study drug administration. Withdrawals after study drug administration will not be replaced. All participants will be healthy adults aged (21-55) years, with a BMI within the accepted range of 18.5-30 kg/m², and will meet the study's selection criteria.

Read the detailed description

This is an Open-Label, Single-center, Randomized, Single-Dose, Two-Way Crossover Biosimilarity Study to Determine the Comparative Pharmacodynamics of Enoxaparin Sodium Biosimilar with that from the Reference IMP, Clexane, Following Single-Dose Administration in Healthy Participants.

The data that will be collected include:

  • Participant identification data
  • Demographic data
  • Smoking habits, caffeine use, medication use, alcohol consumption.
  • Details of prior participation in any clinical or bioequivalence study.
  • Participant medical history, physical examination
  • Vital signs, laboratory results, ECG examination, drug abuse \& alcohol test
  • Study Drug Information: Details of the administered drug, including time of administration.
  • Concomitant Medications
  • Blood sampling intervals for Pharmacodynamic (PD) analysis.
  • Safety Monitoring: Documentation of any adverse events (AEs) Sample Collection and Sample Processing An intravenous cannula will be inserted before the pre-dose sample and will remain until 24 hours post-dose. Blood samples will be collected through an indwelling cannula placed in a forearm vein using a disposable syringe. If difficulty occurs in blood withdrawing or Participants not feeling comfortable with cannula, cannula will be removed, and remaining blood samples will be collected through fresh vein puncture or by re-cannulation. 5 ml of blood samples will be withdrawn and transferred into sodium citrate collection tubes at each time interval. After collection of blood samples placed in a wet ice container equivalent to the approximate height of the blood in the tube till centrifugation, then after centrifugation, transferred into an ice box containing wet ice and stored at -70°±15° immediately. After the collection of blood samples from all Participants at each time interval, samples will be centrifuged at 3500 RPM for 10 minutes.

All plasma samples will be transferred into pre-labeled (Study code, Participant No., Period, Sampling time point) polypropylene tubes. The polypropylene tubes will be transferred to freezer area in an icebox containing wet ice, and the polypropylene tubes will be stored at -70°±15° freezers. Total Number of Blood Samples: 19 samples in each study period. Volume of each sample: 5 ml. Sampling Hours: pre-dose and 0.5, 1.0, 1.5 (1 h 30 min), 2.0, 2.333 (2 h 20 min), 2.667 (2 h 40 min), 3.0, 3.333 (3 h 20 min), 3.667 (3 h 40 min), 4.0, 4.5 (4 h 30 min), 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, and 24.0 h after dose administration Statistical analysis of primary endpoints for the two periods will include descriptive Statistics, ANOVA, and Confidence Interval (C.I.) of enoxaparin. The equivalence of the products will be concluded if the two -one -sided T-test 90 % confidence interval for the test to reference ratio means is within 80.00 - 125.00 % for each of the ln-transformed data of the following primary endpoints: For Anti-Factor Xa: Anti-Xa Amax, and Anti-Xa AUEC0-t , \& For Anti-Factor IIa: Anti-IIa Amax and Anti IIa AUE0-t and finally if there were no safety concerns and both products were well tolerated by the study Participants.

02

Conditions studied

  • Healthy Participants Study
  • The Focus of the Study is to Determine the Comparative Pharmacodynamic of Enoxaparin Sodium With That of Clexane in Healthy Human Participants

Keywords

  • Enoxaparin Sodium
  • Pharmacodynamics
  • Clexane
  • Randomized
  • Healthy participants
  • single dose
03

In context

Lead sponsor

Egyptian International Pharmaceutical Industries Co is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants aged 21 to 55 years at the time of the first dose administration.
  • (BMI) between 18.5 and 30 kg/m², and body weight of at least 45 kg.
  • Participants must have vital signs within the normal range, as defined below, measured at pre-dose:
  • Blood Pressure: Systolic 100-130 mmHg, Diastolic 70-90 mmHg.
  • Pulse Rate: 60-100 beats per minute (bpm).
  • Body Temperature: 36.1-37.2

Exclusion criteria

Exclusion Criteria:

  • to Enoxaparin or any of the formulation
  • to enoxaparin or related group of drugs, which includes but not limited to significant bleeding disorders, thrombocytopenia, blood-clothing disorders, and increased risk of bleeding.
  • History or presence of any medical condition or disease according to the opinion of the principal Investigator
  • History or presence of significant alcoholism or drug abuse in the past one year.
  • History or presence of heavy smoking (≥10 cigarettes or consumption of tobacco products and refusal to restrain from smoking or consumption of tobacco products for 48.00 hours before dosing until checkout of the study).
  • History or presence of significant renal, hepatobiliary, or liver impairment; a medical or familial history of seizures; significant asthma, urticaria, or other allergic reactions; or any other significant medical condition as determined by the Principal Investigator or their delegate.
  • History of difficulty with donating blood or difficulty in accessibility of veins
  • Use of any prescribed medication, OTC medicines or herbal medicines during the last two weeks preceding the first dosing
  • Participants who have any food allergy, intolerance, restriction, or special diet during the four weeks before screening
  • Participation in a drug research study within the past 2 months planned day of first dose administration
  • Donation of blood in the past 2 months before screening
  • Refusal to abstain from food (fasting) for at least ten hours before dosing
  • Refusal to abstain from alcohol or methylxanthine-containing beverages
  • Participants with a positive test for HBs-Ag, -Ab, or -Ab
  • Participant with a positive drug abuse test in urine at screening or at the time of check-in
  • Participant with abnormal baseline coagulation parameters, such as prolonged PT (if greater than 1.2 to 1.5 times the of approximately 11 to 15 seconds), (if greater than 1.5 to 2.5 times the ULN of 25 to 40 seconds), or INR values (is above 1.4) outside the normal reference range.

This is to minimize bleeding risk and confounding effects on study outcomes.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Active comparator
    helathy volunteers

    A minimum of 21 healthy adult male and female participants from Egyptian population will be enrolled in this study, along with 5 additional participants to account for potential dropouts or withdrawal. 26 Participants plus 1-4 alternates will be admitted to the study. An alternate participant will be dosed by the same sequence as the withdrawn participant only if any participant of the first 26 Participants withdraws before the first study drug administration. Withdrawals after study drug administration will not be replaced. All participants will be healthy adults aged (21-55) years, with a BMI within the accepted range of 18.5-30 kg/m², and will meet the study's selection criteria. Test: Enoxaparin Sodium (Enoxaparin Sodium 40mg/0.4ml Reference: Clexane (Enoxaparin Sodium 40mg/0.4ml

    Biological: Enoxaparin 40 Mg/0.4 mL Injectable Solution

Interventions

  • BiologicalEnoxaparin 40 Mg/0.4 mL Injectable Solution

    Drug page: Enoxaparin

    Enoxaparin Sodium (Enoxaparin Sodium 40mg/0.4ml) manufactured by EIPICO, Egypt.

06

What researchers measure

Primary outcomes

  1. Primary Endpoints

    Anti-Xa max: The maximum observed anti-Factor Xa activity in plasma following a single dose

    Time frame: 4 months

  2. Primary outcome 2

    AUEC0-t (Area under the Effect Curve from time zero to last quantifiable time): The area under the anti-Xa effect-time curve from time zero (dosing) to the last measurable time point (T).

    Time frame: 4 months

Secondary outcomes

  1. Secondary outcome

    AUEC0-inf (Area under the Effect Curve extrapolated to infinity): The total area under the anti-Xa effect-time curve, extrapolated to infinity

    Time frame: 3 months

  2. Secondary outcome 2

    Tmax (Time to maximum effect): The time post-dose at which the maximum anti-Xa activity occurs.

    Time frame: 3 months

  3. Secondary outcome 3

    T½ (Half-life of anti-Xa activity): The time required for the anti-Xa activity to decline by 50% during the terminal phase.

    Time frame: 3 months

  4. Secondary outcome 4

    λz (lambda z): The elimination rate constant of the anti-Xa activity. It is a pharmacokinetic parameter describing the rate at which the anti-Xa activity decreases in the plasma over time. It represents the slope of the terminal phase on a concentration-vs-time curve (logarithmic scale).

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Jun 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Apr 8, 2026
StartEst.
Apr 30, 2026
Primary completionEst.
Jun 2026
CompletionEst.
Aug 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07517289
Lead sponsor
Egyptian International Pharmaceutical Industries Co
Responsible party
Sponsor
First posted
Apr 8, 2026
Start date
Apr 30, 2026 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Apr 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin

Start the discussion